Dear Dr. Konecne:

Please refer to your supplemental new drug application dated September 15, 2000, received September 21, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Aredia (pamidronate disodium injection).

We acknowledge receipt of your submission dated April 8, 2003 which constituted a complete response to our December 20, 2002 action letter.

This supplemental new drug application provides additional information for the Hepatic Insufficiency subsection of the Clinical Pharmacology section. This application was submitted in response to a postmarketing commitment in the October 31, 2001 approval letter for NDA 20-036.

We have completed the review of this supplemental application, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted April 8, 2003) with the following change. In the Hepatic Insufficiency subsection of the Special Populations section, add the sentence "Aredia has not been studied in patients with severe hepatic impairment." to the end of the paragraph. (b)(4)---------------------------------------------------------

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-036/S-020." Approval of this submission by FDA is not required before the labeling is used.
If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD  20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff
10/9/03 03:14:39 PM